De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Exelixis Beheer
Beheer criteriumcontroles 3/4
De CEO Exelixis' is Mike Morrissey, benoemd in Jul2010, heeft een ambtstermijn van 14.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.42M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.56% van de aandelen van het bedrijf, ter waarde $ 41.21M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.1 jaar en 7.3 jaar.
Belangrijke informatie
Mike Morrissey
Algemeen directeur
US$16.4m
Totale compensatie
| Percentage CEO-salaris | 7.3% |
| Dienstverband CEO | 14.3yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 9.1yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult
Sep 02
Exelixis Comes Up Aces
Aug 08If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Jun 14It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year
May 24Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
May 07Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$350m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | n/a | n/a | US$208m |
| Sep 30 2023 | n/a | n/a | US$92m |
| Jun 30 2023 | n/a | n/a | US$164m |
| Mar 31 2023 | n/a | n/a | US$154m |
| Dec 31 2022 | US$17m | US$1m | US$182m |
| Sep 30 2022 | n/a | n/a | US$308m |
| Jun 30 2022 | n/a | n/a | US$273m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$8m | US$1m | US$231m |
| Sep 30 2021 | n/a | n/a | US$164m |
| Jun 30 2021 | n/a | n/a | US$94m |
| Mar 31 2021 | n/a | n/a | US$65m |
| Dec 31 2020 | n/a | n/a | US$112m |
| Sep 30 2020 | n/a | n/a | US$152m |
| Jun 30 2020 | n/a | n/a | US$282m |
| Mar 31 2020 | n/a | n/a | US$294m |
| Dec 31 2019 | n/a | n/a | US$321m |
| Sep 30 2019 | n/a | n/a | US$612m |
| Jun 30 2019 | n/a | n/a | US$642m |
| Mar 31 2019 | n/a | n/a | US$650m |
| Dec 31 2018 | n/a | n/a | US$690m |
| Sep 30 2018 | n/a | n/a | US$368m |
| Jun 30 2018 | n/a | n/a | US$323m |
| Mar 31 2018 | n/a | n/a | US$253m |
| Dec 31 2017 | n/a | n/a | US$154m |
Compensatie versus markt: De totale vergoeding ($USD 16.42M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).
Compensatie versus inkomsten: De vergoeding van Mike is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Mike Morrissey (63 yo)
14.3yrs
Tenure
US$16,423,307
Compensatie
Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 29.8yrs | US$519.97k | 0.43% $ 32.6m | |
| CEO, President & Director | 14.3yrs | US$16.42m | 0.56% $ 41.8m | |
| Executive VP & CFO | 9.3yrs | US$4.95m | 0.16% $ 11.9m | |
| Executive VP of Discovery and Translational Research & Chief Scientific Officer | 1.8yrs | US$5.65m | 0.076% $ 5.7m | |
| Executive VP | 10.7yrs | US$4.56m | 0.13% $ 9.7m | |
| Executive VP | 1.2yrs | US$7.38m | geen gegevens | |
| Executive Vice President of Public Affairs & Investor Relations | 7.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Drug Safety | 9.5yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Medical Affairs | 9.1yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Commercial | 7.8yrs | US$4.65m | 0.048% $ 3.6m | |
| VP & Head of Business Development | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Strategy | no data | geen gegevens | geen gegevens |
9.1yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van EXEL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Chair of the Board | 29.8yrs | US$519.97k | 0.43% $ 32.6m | |
| CEO, President & Director | 14.3yrs | US$16.42m | 0.56% $ 41.8m | |
| Independent Director | 20.7yrs | US$490.97k | 0.12% $ 8.7m | |
| Independent Director | 20.2yrs | US$482.22k | 0.063% $ 4.7m | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | less than a year | geen gegevens | 0% $ 0 | |
| Independent Director | less than a year | geen gegevens | 0% $ 0 | |
| Independent Director | 8.1yrs | US$490.92k | 0.00027% $ 20.3k | |
| Independent Director | 6.5yrs | US$488.72k | 0.025% $ 1.9m | |
| Independent Director | 1.4yrs | US$717.44k | 0.0016% $ 119.3k | |
| Independent Director | 1.4yrs | US$716.19k | 0.0016% $ 119.3k |
7.3yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van EXEL wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).